Zorvolex

Contusions, Pain, Photophobia + 54 more

Treatment

10 FDA approvals

20 Active Studies for Zorvolex

What is Zorvolex

Diclofenac

The Generic name of this drug

Treatment Summary

Diclofenac is a type of non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. It works by blocking enzymes that cause the production of substances in the body that cause inflammation and pain. Diclofenac is the product of a rational drug design and is often prescribed as a first-line therapy for various types of pain and inflammation. It is often used in combination with a medication called misoprostol to prevent stomach ulcers caused by NSAIDs. Diclofenac was first approved by the FDA in 1988 under the brand name Voltaren.

Voltaren

is the brand name

image of different drug pills on a surface

Zorvolex Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Voltaren

Diclofenac

1988

767

Approved as Treatment by the FDA

Diclofenac, also called Voltaren, is approved by the FDA for 10 uses including Osteoarthritis of the Knee and Pain .

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Pain

Helps manage Pain

Postoperative Inflammatory Response

Chronic Pain

Helps manage Pain

Osteoarthritis (OA)

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Stomach Ulcer

Used to treat develop NSAID-induced gastric ulcers in combination with Misoprostol

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Osteoarthritis

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Rheumatoid Arthritis

Cataract Surgery

Effectiveness

How Zorvolex Affects Patients

Diclofenac is an anti-inflammatory drug used to reduce pain and fever. Unfortunately, it can also reduce the amount of mucus in the stomach that helps protect it from ulcers.

How Zorvolex works in the body

Diclofenac works by blocking enzymes responsible for creating molecules that cause pain and inflammation. It also affects how neurons respond to pain signals, making them less sensitive. Diclofenac also reduces swelling by stopping white blood cells from flowing to sites of inflammation. It blocks molecules that cause vasodilation and increase nutrient flow, too. In addition, it can reduce the body's overall immune response and stop certain molecules from crossing the blood-brain barrier, thus reducing fever.

When to interrupt dosage

The proposed dosage of Zorvolex is contingent upon the diagnosed condition, including Joint Pain, Postoperative Inflammatory Response and Osteoarthritis (OA). The quantity of dosage alters, per the administration modality (e.g. Cream; Kit; Solution or Kit; Oil; Solution / drops) identified in the table below.

Condition

Dosage

Administration

Contusions

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Photophobia

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Muscle Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Surgery, Dental

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Fever

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Postoperative Inflammatory Response

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Wounds, Nonpenetrating

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

perioperative miosis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Postoperative

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Rheumatoid Arthritis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Rheumatism

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Osteoarthritis of the Knee

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Conjunctivitis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Inflammation

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

strabismus surgery

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Sprains and Strains

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Ankylosing Spondylitis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release - Oral, Tablet, delayed release, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled - Oral, Capsule, liquid filled, Liquid - Ophthalmic, Tablet, extended release, Tablet, extended release - Oral, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit, Oral; Topical, Kit - Oral; Topical, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Sublingual

Warnings

Zorvolex Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Heart failure

Do Not Combine

Crohn's Disease

Do Not Combine

recent history of anal bleeding

Do Not Combine

Hemorrhagic Disorders

Do Not Combine

Gastritis

Do Not Combine

inflammatory lesions of the Rectum

Do Not Combine

active Gastrointestinal Bleeding

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

active Gastrointestinal Perforation

Do Not Combine

Duodenal Ulcer

Do Not Combine

Coronary Artery Bypass Grafting

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Ulcerative Colitis

Do Not Combine

Liver Diseases

Do Not Combine

Stroke

Do Not Combine

Third trimester of pregnancy

Do Not Combine

Hematochezia

Do Not Combine

Kidney Failure

Do Not Combine

Kidney Failure

Do Not Combine

Anus

Do Not Combine

Ulcer

Do Not Combine

damaged skin

Do Not Combine

Gastric ulcer

Do Not Combine

Peptic Ulcer

Do Not Combine

Hyperkalemia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Diclofenac may interact with Pulse Frequency

There are 20 known major drug interactions with Zorvolex.

Common Zorvolex Drug Interactions

Drug Name

Risk Level

Description

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Diclofenac.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Diclofenac.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Diclofenac.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Diclofenac.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Diclofenac.

Zorvolex Toxicity & Overdose Risk

Symptoms of Voltaren overdose may include tiredness, drowsiness, nausea, vomiting, stomach pain, and bleeding from the digestive tract. High blood pressure, kidney failure, shallow breathing, or coma can occur in rare cases. If the overdose happened within the last 4 hours, medical professionals may induce vomiting and administer activated charcoal.

image of a doctor in a lab doing drug, clinical research

Zorvolex Novel Uses: Which Conditions Have a Clinical Trial Featuring Zorvolex?

491 active clinical trials are currently underway to assess the potential of Zorvolex in ameliorating Inflammation, Argon Laser Trabeculoplasty and Osteoarthritis of the Knee.

Condition

Clinical Trials

Trial Phases

Chronic Pain

123 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Early Phase 1, Phase 1

Inflammation

57 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 3, Phase 4

Osteoarthritis of the Knee

72 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Rheumatoid Arthritis

54 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2, Phase 4

Postoperative Pain

21 Actively Recruiting

Phase 4, Not Applicable, Phase 2, Phase 1, Phase 3

Dysmenorrhea

1 Actively Recruiting

Not Applicable

Muscle Pain

3 Actively Recruiting

Phase 4, Not Applicable, Phase 2

Conjunctivitis

0 Actively Recruiting

Musculoskeletal System

1 Actively Recruiting

Not Applicable

corneal refractive surgery

0 Actively Recruiting

Postoperative Inflammatory Response

0 Actively Recruiting

Photophobia

3 Actively Recruiting

Not Applicable

Pain

3 Actively Recruiting

Not Applicable

Stomach Ulcer

0 Actively Recruiting

Rheumatism

0 Actively Recruiting

Juvenile arthritis

6 Actively Recruiting

Phase 2, Not Applicable, Phase 3

radial keratotomy

0 Actively Recruiting

Joints

0 Actively Recruiting

Pericarditis

2 Actively Recruiting

Phase 2, Phase 3

Acute Coryza

0 Actively Recruiting

Zorvolex Reviews: What are patients saying about Zorvolex?

5

Patient Review

3/30/2016

Zorvolex for Pain

Even with my insurance and the savings card, Zorvolex is going to cost $193.00 for a 30 day supply--which is way too much. 800 mg of Iburophen works just as well for me and it's a lot cheaper.

5

Patient Review

9/9/2015

Zorvolex for Joint Damage causing Pain and Loss of Function

Before taking this medication, I could hardly get out of bed. Walking was a real challenge. But this drug has helped me immensely and I am now able to live a relatively normal life again.

5

Patient Review

10/14/2016

Zorvolex for Pain

Though it does require a bit of budgeting for the copay, this treatment has been well worth it for me. It's helped with mysciatic pain, spinal stenosis, and osteoarthritis in my hands. I can definitely tell when I miss a dose.

5

Patient Review

6/15/2016

Zorvolex for Joint Damage causing Pain and Loss of Function

I unfortunately got microscopic colitis after taking this medication. The diarrhea that resulted was truly awful. I had to take a steroid to get it under control, and my doctor says I'll have it for the rest of my life.

5

Patient Review

8/11/2017

Zorvolex for Inflammation of the Sac Surrounding the Joint - Bursitis

I found an old bottle of Zorvolex in my drawer, and even though it had expired by a full year, I decided to give it a try because the online reviews said it would help with inflammation. I'm so glad I took that chance! The pill worked amazingly, reducing the swelling and pain almost immediately. It was such a relief that I went back to my doctor and asked for more.

5

Patient Review

10/9/2017

Zorvolex for Joint Damage causing Pain and Loss of Function

Zorvolex has been an incredible help for my aching knees and back. I was struggling to even walk before taking this medication, but now I feel like I have new joints!

5

Patient Review

7/31/2015

Zorvolex for Joint Damage causing Pain and Loss of Function

Zorvolex completely alleviated the inflammation and pain I experience with Lupus and Sjogrens. No other medication has given me such relief, and without any side effects!

5

Patient Review

5/8/2015

Zorvolex for Joint Damage causing Pain and Loss of Function

This treatment has been effective in helping me to forget about my back issues and the pain that comes with it.

4.7

Patient Review

3/13/2016

Zorvolex for Inflammation of the Tendon

I was given samples of this medication from my doctor for inflammation and pain. I took it for less than two weeks, during which time I gained over 10 pounds. Not only did it not help with my pain, but it also caused me to gain a significant amount of weight.

4.7

Patient Review

4/2/2015

Zorvolex for Gout

4.3

Patient Review

7/10/2016

Zorvolex for Rheumatoid Arthritis

I was given this medication two years ago and it's been really effective at managing my pain without requiring me to take a lot of medication.

2.7

Patient Review

3/16/2016

Zorvolex for Pain

This drug helped me manage the pain of Plantar fasciitis for a while, which was greatly appreciated. However, after some time the pain subsided on its own and I no longer needed to take this medication.

2.3

Patient Review

11/12/2016

Zorvolex for Pain

This medication didn't do much to help with my pain. I'm not impressed and would like to try something else.

2.3

Patient Review

5/19/2015

Zorvolex for Pain

I was pleasantly surprised by how quickly this medication took effect. I haven't needed to use my opiate prescription today, which is a huge relief.

2

Patient Review

5/1/2016

Zorvolex for Acute Pain

Within a few days, this treatment helped lessen the pain of plantar fasciitis. I only use it now when absolutely necessary.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zorvolex

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why was Zorvolex discontinued?

"ZORVOLEX is not recommended for use in patients undergoing CABG surgery due to the increased risk of serious gastrointestinal adverse events associated with NSAIDs. These events can include bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal."

Answered by AI

How much Zorvolex should I take?

"For mild to moderate acute pain, the dosage is 18 mg or 35 mg orally three times daily. For osteoarthritis pain, the dosage is 35 mg orally three times daily."

Answered by AI

What is the difference between Zorvolex and diclofenac?

"ZORVOLEX is available in lower dosage strengths (18-mg and 35-mg capsules) compared with other formulations of diclofenac which contain the sodium or potassium salt of diclofenac (Figure 2)."

Answered by AI

What is the drug Zorvolex used for?

"It is used to relieve pain from various conditions such as muscle aches, backaches, dental pain, menstrual cramps, and sports injuries. By reducing symptoms such as pain, swelling, and stiffness, it allows patients to return to their normal daily activities."

Answered by AI

Clinical Trials for Zorvolex

Image of West Virginia University in Morgantown, United States.

5-fluorouracil + Aluminum for Actinic Keratosis

18 - 50
All Sexes
Morgantown, WV

Actinic keratoses (AKs) are precancerous skin lesions most common among older white individuals and are prevalent throughout West Virginia. There is a risk of progression to cutaneous squamous cell carcinoma (SCC) when lesions are left untreated. Field-directed therapy with topical agents is used for patients with multiple lesions in a contiguous area. We propose that aluminum utilized for hemostasis is a contributing factor in the tumor regression seen after some biopsies and may be effective as an augmenting agent for topical management of AKs. The primary objective of this study is to determine the effectiveness of using aluminum as an augmenting agent in traditional Standard of Care (SOC) topical cream to treat AKs by assessing the response of AKs to treatment with 5% 5-FU plus 15% aluminum chloride hexahydrate (ACH) cream and comparing the reduction in the number/burden of lesions to SOC topical treatment (5% 5-fluorouracil (5-FU)). Photographs and total counts of AKs will be taken by a single dermatologist before (day 0), immediately after (day 8), and 8 weeks after (day 56) treatment.

Phase 1
Waitlist Available

West Virginia University

Joanna Kolodney, MD

Image of Steadman Philippon Research Institute in Vail, United States.

Leg Dexterity Trainer for Osteoarthritis

40 - 85
All Sexes
Vail, CO

Rationale: Roughly 14 million adults aged 60 or older (10% male/13% female) in the United States experience symptoms of knee osteoarthritis (OA). Knee OA pain progressively impacts aging, reducing mobility and increasing morbidity. Nonsurgical self-management of knee OA includes exercise to promote proper knee mechanics, non-steroidal anti-inflammatory drugs (NSAIDs), cortisone injections, and weight loss to reduce pain and retain function. As OA has no cure, self-management progresses to \~1 million joint replacements per year. Critically, home-based devices are lacking for specifically training the low-level proprioceptive and neuromuscular circuitry for proper knee mechanics in a safe, focused, mechanistic way. Such devices would supplement exercises for strength, mobility, and whole-body loading and movement. Initially considered a wear-and-tear condition, knee OA is now understood as a complex disease involving inflammatory responses to mechanical loading and neuromuscular feedback loops among pain, joint damage, and dynamic loading. Home-based exercises remain a primary nonpharmacological and nonsurgical approach to managing chronic pain in OA that fundamentally disrupts proprioception and neuromuscular control of the joint, which accelerates articular degeneration. Neuromuscular Dynamics, LLC has developed a simple, safe, quick, and effective Leg Dexterity System that is portable, wireless, and coupled to HIPAA-compliant cloud analytics. A seated participant uses their foot to compress a platform atop a slender spring, which becomes unstable as it begins to buckle at low forces. The participant must then control their leg dexterity (i.e., via short-latency sensorimotor circuits) to stabilize the unstable dynamic foot-ground interactions. A tablet computer connected to the device provides feedback during use and uploads the participant's activity data to the server for analysis and reporting, accessible to users and clinicians. The investigators have successfully tested Leg Dexterity in control participants in multiple publications. The Leg Dexterity test is safe and poses minimal risk as the forces needed to do it are very low, does not involve full weight- bearing maneuvers, and is performed while seated without the risk of falling. Study: The investigators will conduct a randomized home-based clinical trial in knee OA to demonstrate the efficacy of leg dexterity training to reduce pain and improve function compared to currently prescribed dynamic exercise on a wobble board (a commonly used approach for improving proprioception and balance). Successful completion of this study will justify the adoption of the Leg Dexterity System as an effective at-home supplement to any nonsurgical management of knee OA. The investigators propose a longitudinal double-blind dose-matched trial comparing 8 weeks of leg dexterity training (Treatment using a slender, unstable spring system that engages short-latency sensorimotor control, 42 participants) vs. at-home wobble board exercises (Control, 42 participants) at the Steadman Philippon Research Institute.

Recruiting
Has No Placebo

Steadman Philippon Research Institute

Scott Tashman, PhD

Image of University of California, Irvine, Emergency Department in Orange, United States.

Music Therapy for Pain

18 - 75
All Sexes
Orange, CA

Studies have shown that 60-70% of patients in the Emergency Department (ED) experience pain. With pain being such a broad issue in the ED, the ED is expected to deliver safe and effective treatment of pain. However, with the current ongoing opioid epidemic, it is important to consider other methods, both pharmacologic and nonpharmacologic, of pain reduction. Jazz music specifically has been demonstrated to have therapeutic effects on pain that can be used to lower the quantity of opioids administered to patients. Non-pharmacological interventions in the emergency department for pain typically consist of splinting an injury, applying heat or cold, or various distractions following initial and sequential pain assessment. Pharmacological interventions for pain in the Emergency Department involve the administration of acetaminophen, muscle relaxers, topical anesthetics, opioids, to name a few. In the emergency department (ED), providers are increasingly hesitant to prescribe opioids over the past decade due to the current opioid epidemic, in which there is an increasing proportion of people that develop an addiction to opioids, including those that are prescribed to them for pain management.. While emergency medicine providers' decrease in opioid prescriptions pertains to their implementation of opioid-prescribing policies, little evidence has been found demonstrating a direct link in these policies to decreases in substance misuse. Consequently, providers find themselves needing to become ingenious in their approach to pain in patients through the integration of pharmacologic and non-pharmacologic mediums of analgesia. A recent randomized controlled trial (RCT) from Brigham and Women's Hospital in Boston sought to identify the qualitative responses from patients in the ED following the arbitrary distribution of either supervised or unsupervised music therapy over a time period of 4 hours. The initial results found that, generally speaking, music therapy may lower reported pain and anxiety scores. Furthermore, stronger results were identified in case subjects with higher initial reports of pain via a pain catastrophizing scale, implying that a higher baseline of pain results in more relief from music therapy. One shortcoming in the article is the lack of analysis with reported results and the biopsychosocial model of pain. Heavy emphasis is placed on the psychological and social components of pain in the Brigham and Women's article through the implementation of the Pain Catastrophizing Scale and Brief Pain Inventory scoring done during the RCT, but no focus on linked biological changes in the subjects through the music therapy intervention. The purpose of this study is to (i.) assess the effect of a video training about musical pain management followed by a 15-minute music listening intervention on self-reported pain scores in ED patients with neck and back pain. The investigators also aim to (ii.) evaluate patient satisfaction and emotional response following the intervention. Opioid medications are commonly used to reduce substantial pain, and music therapy has been found to reduce associated pain and anxiety in patients, then the use of music therapy could be an aid in medicine to reduce opioid intake. The investigators hypothesize that the usage of a training on musical pain management combined with a specified jazz musical intervention will produce a significantly lower measured pain score in comparison to a video on mindful pain management followed by the patient's choice of activities.

Waitlist Available
Has No Placebo

University of California, Irvine, Emergency Department

Sean Young, PhD

Image of Exercise and Performance Nutrition Laboratory in Saint Charles, United States.

Multi-Strain Postbiotic for Inflammation and Gastrointestinal Symptoms

18 - 55
All Sexes
Saint Charles, MO

This study will evaluate the effects of a multi-strain postbiotic supplement on markers of inflammation, immune function, gastrointestinal symptoms, psychological well-being, and intestinal permeability in healthy adults. The primary objective is to determine whether four weeks of postbiotic supplementation alters physiological and perceptual responses to a standardized bout of moderate-to-high intensity exercise compared with placebo. Approximately 50 healthy men and women aged 18 to 55 years will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Participants will be randomly assigned to receive either a multi-strain postbiotic supplement or a matched placebo for 28 days. At the end of the supplementation period, participants will complete a 45-minute treadmill exercise bout at 75% of their individually determined maximum heart rate. Blood samples will be collected to assess biomarkers of inflammation, immune activity, and recovery. Gastrointestinal symptoms, intestinal permeability, anxiety, and perceived recovery will be evaluated using validated questionnaires. This study is designed to determine whether postbiotic supplementation modulates physiological stress responses and subjective well-being following prolonged exercise in healthy adults.

Waitlist Available
Paid Trial

Exercise and Performance Nutrition Laboratory

Chad M Kerksick, PhD

Have you considered Zorvolex clinical trials?

We made a collection of clinical trials featuring Zorvolex, we think they might fit your search criteria.
Go to Trials
Image of ATX Hyperbarics in Austin, United States.

Hyperbaric Oxygen Therapy for Cardiovascular Fitness

30 - 60
All Sexes
Austin, TX

The purpose of this study is to determine whether hyperbaric oxygen therapy (HBOT) at 1.75 atmospheres of pressure (ATA) improves cardiovascular fitness (VO₂ max) and reduces inflammation in healthy adults. HBOT involves breathing pure oxygen in a pressurized chamber and is considered investigational for this use. Recent research has shown that different HBOT pressures can have different effects on inflammation. Specifically, some inflammatory cytokines (measurable markers of inflammation in the body) appear to decrease at low pressures like 1.3 ATA, while a different set of cytokines responds better at higher pressures, such as 2.0 ATA. Cytokines are small proteins that play a crucial role in cell signaling, particularly within the immune system. They help regulate inflammation, infection response, and overall immune function. While some cytokines promote inflammation to fight off threats, others help reduce inflammation when it's no longer needed. An imbalance in cytokines - especially excessive inflammatory cytokines - can contribute to chronic inflammation, cardiovascular disease, and other health issues. In this study, we are testing an intermediate pressure - 1.75 ATA - to see if we can target both sets of cytokines at once. If successful, this approach could offer broader anti-inflammatory benefits. We are also interested in how this intermediate pressure may improve VO₂ max, a key indicator of cardiovascular fitness. Since VO₂ max is strongly linked to heart health and overall longevity, finding a safe and effective way to improve it has meaningful implications not just for athletes, but for anyone looking to enhance their fitness and well-being.

Recruiting
Has No Placebo

ATX Hyperbarics (+1 Sites)

Image of University Center for Ambulatory Surgery in Somerset, United States.

Infusion Pump for Postoperative Pain

18+
All Sexes
Somerset, NJ

This study will be a pragmatic, prospective cluster randomized trial, where clusters will formed based on sequential 2 week time increments across the study recruitment period.. Patients 18 years or older undergoing ACL reconstruction, open shoulder labrum or rotator cuff surgery, arthroscopic rotator cuff repair, proximal or distal patellar realignment surgery, open knee arthrotomy cases (i.e. inside out meniscus repair, osteochondral allograft transplantation (OCA), meniscal allograft transplantation (MAT)) at University Center for Ambulatory Surgery, LLC (UOA) will be reviewed for eligibility. Once identified, potential study subjects will be asked whether they are interested in participating in the project. If the patient agrees, the subject will be given the informed consent to read and sign. Objectives: The primary objective is to compare the effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period. The second objective is to evaluate the requirement of narcotic and non-narcotic analgesic medications between the two groups. Hypotheses: Use of continuous infusion pain pump or single shot peripheral block will result in similar post-operative pain control after outpatient sports medicine surgical cases.

Phase 4
Recruiting

University Center for Ambulatory Surgery

Image of Montana State University in Bozeman, United States.

Haskap Berries for Exercise Performance Recovery

18 - 35
All Sexes
Bozeman, MT

The purpose of this clinical trial is to determine how certain food items affect oxidative stress, inflammation, and performance recovery from exercise induced muscle damage in a resistance trained population. The main questions The investigators aim to answer are the following: * Do Haskaps speed the recovery of oxidative stress and inflammation markers after an intense lower body workout in resistance trained adults? * Do Haskaps speed the recovery of performance measures after an intense lower body workout in resistance trained adults? * The data collected in this investigation may also be used to ask additional questions not yet identified. For example, the investigators may use the stored samples to evaluate how the blood metabolites of participants differ before and after intense exercise. These additional questions are called secondary analyses. Please note that no genetic analysis will be conducted and racial and ethnic differences among participants will not be used in any secondary analyses. Researches will compare Haskap juice to a color, flavor and carbohydrate matched placebo to see if Haskaps speed recovery in inflammation, oxidative stress and performance. * Participants will be asked to drink either Haskap juice or placebo and follow a low polyphenolic diet * Participants will perform an intense resistance workout * Participants will have their blood drawn before and after the workout * Performance will be analyzed at 24, 48 and 72 hours after the workout

Recruiting
Paid Trial

Montana State University

Mary P Miles

Image of University of North Carolina at Chapel Hill in Chapel Hill, United States.

Pain Medicines for Period Pain in Crohn's Disease

18 - 44
Female
Chapel Hill, NC

The purpose of this pilot study is to prepare for a larger study that will compare the effectiveness and safety of two common pain medications, ibuprofen and acetaminophen, to help treat period cramps in women with Crohn's disease. The goal of this study is to identify any challenges in running a larger study. The investigators will track how many people sign up for the study, how well participants follow the study plan, how many people stay in the study, and whether they are able to complete all the study activities, such as taking the medication, submitting samples, and filling out surveys. During the study, participants will undergo a screening visit that includes a blood draw, physical exam, pregnancy test, stool testing, and complete surveys about Crohn's disease and menstrual cycles. Once this visit is complete, the rest of the study will occur at home. Participants will be assigned to take either ibuprofen or acetaminophen to help treat period cramps for four menstrual cycles in a row. Participants will take ibuprofen for two cycles and acetaminophen for two cycles. Participants will know which medication is being taken at any given time, but the order in which they take the medications will be randomly assigned. Before each menstrual cycle, participants will submit a stool sample and fill out a short (\<1 minute) electronic survey. When participants develop period cramps, they will take the assigned medication for three days and fill out short (\<1 minute) electronic surveys about their cramps. After participants finish taking the medication for three days, they will submit another stool sample and fill out two more short (\<1 minute) electronic surveys. After have completing this process for four menstrual cycles, a remote interview with a researcher to give feedback on the study will be conducted.

Waitlist Available
Has No Placebo

University of North Carolina at Chapel Hill

Erica J Brenner, MD, MSCR

Have you considered Zorvolex clinical trials?

We made a collection of clinical trials featuring Zorvolex, we think they might fit your search criteria.
Go to Trials
Image of Byers Eye Institute in Palo Alto, United States.

LLM-Based Education for Cataract Surgery

18+
All Sexes
Palo Alto, CA

Patients with cataracts disease need to choose what type of artificial lens will go into their eye prior to surgery date. Some lenses are standard and are usually covered by insurance. Other "premium" lenses have various benefits such as reducing the need for glasses but usually require out-of-pocket costs. The combined busy outpatient clinic and complexity of artificial lens choices in the ever-changing world of cataract surgery tends to lead patients confused about their available lens options. There is an abundance of educational material present in premium lenses, however these are limited by accessibility and are standardized at single educational levels. Therefore in the present study, we want to test whether giving patients a short LLM powered AI-guided explanation from Custom GPT from OpenAI of lens options prior to their consultation with their doctor can improve visit efficiency, physician explanation and patient understanding of lens options. We will compare two groups: standard of care versus standard of care plus AI education. The LLM in this study is intended to provide supplemental information about premium intraocular lens(IOLs) options to study participants, and is no means supposed to replace a health care professional in the diagnosis, cure, treatment, and/or mitigation of disease. Study is analogous to giving a verified health pamphlet to a patient for them to view and learn different IOL options, in other words, facilitating patient understanding of their options. The LLM will be trained by several health care professionals and MD specialists to provide sufficient instructions. Sources will include verified online resources and MD information. The investigators hope to learn if a large language model-based educational tool can improve visit efficiency, physician explanation and patient understanding of intraocular lens options. New knowledge of this study could guide how cataract counseling is delivered in the future and may help clinics spend more time on individualized questions instead of repeating generic information.

Waitlist Available
Has No Placebo

Byers Eye Institute

Robert T Chang, MD

Have you considered Zorvolex clinical trials?

We made a collection of clinical trials featuring Zorvolex, we think they might fit your search criteria.
Go to Trials